Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingfehuatan decoction is a Traditional Chinese Medicine (TCM) formula developed by the China-Japan Friendship Hospital, specifically indicated for the treatment of bronchiectasis, particularly during acute exacerbations characterized by phlegm-heat obstructing the lungs. The decoction is a complex herbal mixture typically containing ingredients such as *Scutellaria baicalensis* (Huangqin), *Fritillaria thunbergii* (Zhebeimu), and *Morus alba* (Sangbaipi). Its therapeutic effects are attributed to its multi-target anti-inflammatory and mucoregulatory properties. Mechanistically, it has been shown to reduce the levels of pro-inflammatory cytokines, including interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-alpha), in the airways. Additionally, it acts as a mucoregulator by potentially downregulating the expression of MUC5AC, thereby reducing airway mucus hypersecretion and improving mucociliary clearance. Clinical research at the China-Japan Friendship Hospital has focused on its ability to alleviate cough, reduce sputum volume, and decrease the frequency of exacerbations in patients with chronic inflammatory airway diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qingfehuatan decoction.